← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT07488897

RIG 101 Trial in Healthy Adults and Adults With Asthma

Trial Parameters

Condition Healthy Adult Participants
Sponsor RIGImmune Inc.
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 82
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2026-02-09
Completion 2027-02
Interventions
RIG-101Placebo

Brief Summary

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

Eligibility Criteria

Inclusion Criteria: Participants must meet all the following inclusion criteria to be eligible to participate in the trial. * Participants must have a written informed consent obtained prior to any trial related procedure * Male and female participants aged between 18 to 65 years inclusive, at the time of informed consent. * Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator. Additional Inclusion Criteria for Healthy Participants \- Participants must have a pre-bronchodilator FEV1 ≥80% predicted (using GLI Global predicted values17) and an FEV1 / FVC ratio of \>70% absolute at screening. Additional Inclusion Criteria for Participants with Asthma * Participants must have a clinical diagnosis of asthma. * Participants must have either a positive skin prick test with a wheal diameter of ≥3mm greater than control test at 15 minutes, a

Related Trials